Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years

(MedPage Today) -- MADRID -- The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news